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Abstract 
 
Angiogenesis is the formation of new blood vessels from preexisting blood vessels. Design 
and development of novel angiogenesis inhibitors has been validated as a target in several tumor 
types. Integrins are important ligands that play a critical role in the angiogenesis process, 
particularly blood formation and local release of vascular growth factors, and they are members of 
a family of cell surface receptors. Tetraiodothyroacetic acid (tetrac), a deaminated derivative of 
thyroid hormone T4, is a thyroid antagonist and blocks the actions of T3 and T4 with an interaction 
site that is located at or near the RGD recognition site identified on integrin αvβ3’s binding pocket. 
In this study, we synthesized novel mono- and di-amino tetrac analogs and then tested them for 
their anti-angiogenesis activity.  
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5 
Introduction 
  Judah Folkman in 1971, theorized that tumors cannot grow past a size of 1 mm without 
developing their own blood supply. [1] Angiogenesis refers to the “process by which resident 
endothelial cells of the wound’s adjacent mature vascular network proliferate, migrate and remodel 
into neovessels that grow into the initially avascular wound tissue aided by mature stromal cells.” 
[2] In other words, it is the formation of new microvessels from an already established vascular 
network, expanding the already existing network [3]. Similar but still unlike angiogenesis, 
vasculogenesis is the differentiation of precursor cells (angioblasts) into endothelial cells and the 
formation of a primitive vascular network. Vasculogenesis is creating a brand new network, while 
angiogenesis adds to a pre-existing one [4,5]. 
 Angiogenesis occurs by two distinct mechanisms, sprouting and intussusception. 
Intussusceptive angiogenesis begins due to the insertion of interstitial cellular columns into the 
lumen of pre-existing vessels. The growth that follows these columns and their stabilization results 
in partitioning of the vessel and remodeling of the local vascular network. Sprouting angiogenesis 
entails two successive phases: neovessel growth and neovessel stabilization. Both phases are 
equally important because, in the absence of vessel stabilization, the immature capillary will 
rapidly undergo apoptosis and regress [6]. 
 Tumor angiogenesis is a process of new blood vessel growth of tumors from preexisting 
vessels by cell adhesion to the extracellular matrix (ECM) and allows for tumor progression. [7] 
Rapid tumor cell proliferation produces environmental stresses such as a hypoxic, glucose- 
deprived environment that begins the angiogenic switch, whereby tumor cells initiate to spatter 
proangiogenic growth factors, such as fibroblast growth factor (FGF), epidermal growth factor 
(EGF), vascular endothelial growth factor (VEGF), angiopoietin, and thrombospondin (Figure 1) 
6 
[8-10].  
 
Figure 1. Angiogenesis is the process of the development of new blood vessels from preexisting 
vessels, which allows for tumor progression.  The tumor starts off localized but with growth factors 
like FGF, EGF, VEGF, angiopoietin and thrombospondin, the blood vessel is encouraged to grow and 
spread into the tumor. This allows the tumor to grow and spread with the additional blood vessels inside 
the tumor, giving the tumor access to the rest of the body.  
 
One of the important ligands that play a critical role in the angiogenesis process particularly 
blood formation and local release of vascular growth factors, are integrins. They are members of 
a family of cell surface receptors who are immunoglobulin superfamily molecules or ECM proteins 
[11-13]. The integrins consist of α and β chain units including αvβ3, αvβ5, αvβ6, α4β1, α5β4, and α6β4 
are expressed on multiple tumor types (Table 1).  
Table 1. Selected list of integrins in cancer progression 
Integrins expressed Tumor type 
αvβ3  Glioblastoma [14],  cervical [15],  ovarian [16],  
pancreatic [17],  prostate [18],  breast [19-22],  and 
melanoma [23-24] 
αvβ5  Glioblastoma [14] 
αvβ6  Colon [25] and cervical [26] 
α4β1 Ovarian [27] 
α5β1 Non-small-cell lung cancer [28] and melanoma [24] 
α6β4 Breast [30-31] 
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Among them, integrins αvβ3 and αvβ5 are the main receptor types involved in the angiogenesis 
process, particularly in binding with angiogenesis modulators containing arginine-glycine-
aspartate (RGD) that bind to specific recognition site of integrin receptor (identified as the RGD 
recognition site). [32-34] There are several natural RGD containing proteins such as fibronectin, 
fibrinogen, λ-receptor on E. coli, Sindbis coat protein, and α-lytic protease protein as well as cyclic 
RGD tripeptide (c-RGD) and c-RGD peptidomimetics that have shown high binding affinity to 
the recognition site of the integrin (Figure 2) [35-37]. Artificial RGD-containing peptides are 
either cyclic or linear RGD peptides. Cyclic RGD peptides are more active than linear RGD 
peptides because they are conformationally less flexible and metabolically more stable. [38]  
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Figure 2. Chemical structure of arginine-glycine-aspartate (RGD) and some known natural RGD 
containing proteins.  
 
RGD peptides attach to the integrin αvβ3; this integrin is important in angiogenesis and is 
8 
expressed highly in tumor cells. [39] The αvβ3 antagonist inhibits tumor angiogenesis. Due to the 
small size of the RGD peptides, RGD conjugates have easier access to tumor tissues (Figure 2).  
Several studies have reported the effects of thyroid hormone derivatives on thyroid hormone 
receptor (TR) and membrane Na+/H+ antiporter ion pumps via binding to integrin αVβ3. For 
example, angiogenesis activity of thyroid hormone derivatives has been observed with 2-
ammonium-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-propionate (T3) and 2-
ammonium-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl] propionate (T4), and anti-
angiogenesis activity has been observed with tetraiodothyroacetic acid (tetrac) in the chick 
chorioallantoic membrane (CAM) and other angiogenesis models. [40-43] Tetrac is a deaminated 
derivative of T4 and acts as a thyroid antagonist by blocking the actions of T3 and T4 with an 
interaction site that is located at or near the RGD recognition site on integrin αvβ3’s binding pocket. 
(Figure 3A) Tetrac also showed anti-proliferative activity against different cancer cell lines such 
as human non-small cell lung cancer (NSCLC) H1299 cells in vitro and in xenografts as well as 
anti-angiogenic activity at the integrin αvβ3 receptor binding site. [44] For example, Yoshida et al. 
found tetrac to be an effective inhibitor of retinal angiogenesis and was able to inhibit the pro-
angiogenic effect of both VEGF and EPO on retinal endothelial cells; this suggests that tetrac, an 
antagonism of integrin αvβ3, is a viable therapeutic strategy for proliferative diabetic retinopathy 
[45].  
Our group widely uses tetrac for conjugation to the polymeric nanoparticle (NP) poly(lactic-
co-glycolic acid) (PLGA) via covalent binding (an amidation reaction) between tetrac’s outer ring 
hydroxyl to NHS-modified PLGA, which resulted in a tetrac-nanoparticulate. This nanoparticle 
showed anti-angiogenic activity, which confirmed the role of the integrin receptor. (Figure 3B) 
[46-48] Results obtained from both in vitro and in vivo experiments for the treatment of drug-
9 
resistant breast cancer showed that tetrac-conjugated PLGA-NPs were restricted from entering into 
the cell nucleus and enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of 
free tetrac. We concluded that tetrac-conjugated PLGA-NPs have a high potential as anticancer 
agents, with possible applications in the treatment of drug-resistant cancer [47, 49-52]. We also 
synthesized a new analog of tetrac that expresses pro-angiogenic rather than anti-angiogenic 
activity. In order to mimic the action of the iodothyronine deiodinases (the enzymes that convert 
T4 to T3), tetrac was deiodinated using tertiary amines. Tertiary amines initially deprotonated the 
phenolic OH group and subsequent anion extraction of a proton formed a tautomeric dienone. 
Finally, nucleophilic attack on the iodine atom resulted in a deiodinated product of tetrac, 
designated MR-49 [53].  
 
 
Figure 3. A) Pro-angiogenic actions of thyroid hormones (T4 and T3) on endothelial cells and vascular 
smooth cells are initiated at the cell surface receptor for the hormone on the extracellular domain of 
integrin αvβ3. Tetraiodothyroacetic acid (tetrac), a thyroid hormone analog, is inhibitory at the integrin 
receptor and is anti-angiogenic. B) Conjugation of tetrac to a polymeric nanoparticle like poly(lactic-co-
glycolic acid) (PLGA) results in a tetrac-nanoparticulate that has shown anti-angiogenic activity. 
 
 Knowing that the angiogenesis activity of tetrac is stimulated by VEGF or FGF without 
10 
influencing the pre-existing blood vessels, we planned to synthesize new analogs of tetrac by 
modifying the phenolic moiety of tetrac and study their structure-activity relationship. The 
phenolic hydroxyl group (-OH) of thyroid analogs is an important site for modification and a target 
site for converting tetrac to an integrin antagonist without any changes to the carboxylic acid 
moiety of tetrac. As an example, we previously synthesized diamino-tetrac (DAT), which showed 
anticancer/anti-angiogenic activity that was able to target the thyroid hormone-tetrac receptor on 
the extracellular domain of integrin αvβ3.  (Figure 4A) 
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Figure 4. A) The phenolic hydroxyl group (-OH) of tetrac is selected as the modification site and target 
site for converting tetrac to an integrin antagonist without any changes to the carboxylic acid moiety of 
tetrac. B) Conjugation of the phenolic hydroxy group (4’-OH) of thyroxine (T4) with sulfate or 
glucuronic acid yields the corresponding sulfated (T4S) and glucuronidated hormone (T4G), 
respectively. 
 
Wu et al., also showed that conjugation of the phenolic hydroxy group (4’-OH) of thyroxine 
(T4) with sulfate or glucuronic acid yielded the corresponding sulfated (T4S) and glucuronidated 
(T4G) hormone, respectively; sulfate and glucuronic acid conjugations are useful in enhancing the 
water solubility of many hydrophobic drugs and their excretion through urine and/or bile. [54-55] 
Similar to T4S and T4G, tetrac also undergoes sulfation and glucuronidation, thus suggesting that 
12 
the body can integrate drugs into metabolism. [55] (Figure 4B)  
General chemistry and materials  
All commercially available chemicals were used without further purification. All solvents 
were dried and anhydrous solvents were obtained using activated molecular sieves (0.3 or 0.4 nm 
depending on the type of solvent). All reactions (if not specifically containing water as reactant, 
solvent or co-solvent) were performed under an Ar or N2 atmosphere, in oven-dried glassware. All 
new compounds gave satisfactory 1H NMR and mass spectrometry results. Melting points were 
determined on an Electrothermal MEL-TEMP® melting point apparatus and on a Thomas 
HOOVER Uni-mel capillary melting point apparatus. Infrared spectra were recorded on a Thermo 
Electron Nicolet Avatar 330 FT-IR apparatus. UV spectra were obtained from a SHIMADZU UV-
1650PC UV-vis spectrophotometer. The solution-state NMR experiments were all performed on 
a Bruker Advance II 800 MHz spectrometer equipped with a cryogenically cooled probe (TCI) 
with z-axis gradients (Bruker BioSpin, Billerica, MA) at the Center for Biotechnology and 
Interdisciplinary Studies, Rensselaer Polytechnic Institute (RPI, Troy, NY). All tubes used had a 
5 mm outside diameter. NMR data were referenced to chloroform (CDCl3; 7.27 ppm 
1H, 77.20 
ppm 13C) or DMSO-d6 (δ= 2.50 ppm, 38.92 ppm 13C) as internal reference. Chemical shifts δ are 
given in ppm; multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and br (broad); coupling constants, J, are reported in Hz. Thin layer chromatography 
was performed on silica gel plates with a fluorescent indicator. Visualization was accomplished 
by UV light (254 and/or 365 nm) and/or by staining in ceric ammonium molybdate or sulfuric acid 
solution. Flash column chromatography was performed following the procedure indicated by Still 
et al., with 230-400 mesh silica gel. [56] High resolution mass spectral analysis was performed on 
either an Applied Biosystems API4000 LC/MS/MS or Applied Biosystems QSTAR XL mass 
13 
spectrometers.  
Results and discussion 
Synthetic methods for synthesis of tetrac and its analogs 
As shown in Scheme 1, a large scale of compound 7, tetrac, was synthesized according to 
our previously described method. [57] Compound 2, (4-hydroxy-3,5-dinitro-phenyl)-acetic acid 
ethyl ester was obtained from commercially available 4-hydroxy-benzeneacetic acid 1 in the 
presence of nitric acid, acetic acid, and ethanol in 72% yield, which was then reacted with p-
toluenesulfonyl chloride and methoxyphenol in pyridine to give the diphenyl ether derivative 3 in 
75% yield. Two nitro groups of 3 were reduced and converted to amine 4 using a catalytic amount 
of 5% palladium, H2, calcium carbonate and ethanol was the solvent. Compound 4 was then reacted 
with sodium iodide to convert the amine groups to iodine, resulting in 5 in 69 % yield, followed 
by hydrolyzation and deprotection under reflux conditions using hydroiodic acid (HI) as a strong 
cleaving agent for facile removal of both the ester and methyl groups from  product 6. Acetic acid 
was used to avoid decomposition of HI into I2 by H2SO4, thereby avoiding the generation of 
unwanted side products in the reaction medium. The tetrac target molecule 7 was obtained from 
the di-iodo compound 6 by reacting with iodine. In the reaction, iodo-deprotonation was carried 
out using I2 in methanolic-NH3 with near quantitative yields. Regioselective iodination of the ring 
in compound 6 was facilitated by the transformation of the methyl ether group of compound 5 into 
an alcohol in substrate 6. This was done to allow activation of the ortho position in compound 6 
through inductive and resonance effects. 
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Scheme 1. Preparation of tetrac 7; (a) nitric acid, acetic acid, ethanol, 24 h, 72%; (b) p-toluenesulfonyl 
chloride, p-methoxyphenol, pyridine, 3 h, 95-125°C, 75%; (c) catalytic amount of 5% palladium, H2, 
calcium carbonate, ethanol, quantitative yield; (d)  i) sodium nitrate, sulfuric acid/acetic acid (v/v), 0°C, 
2 h, ii) sodium iodide, I2, urea, water/CHCl3 (3/1), RT, 1 h; (e) HI (excess), acetic acid, reflux, 1 h, 95%; 
(f) I2 excess, NH3 excess, CH3OH, 91%. 
 
As mentioned, the phenolic hydroxyl group (-OH) of tetrac was selected as the target site 
for converting tetrac to an integrin antagonist without any changes of its carboxylic acid moiety. 
For each new compound the carboxylic acid moiety is mainly responsible for the ligand-receptor 
interaction, and is involved in the binding of a metal ion (2.6 A from the metal ion) that occurs 
only in the active state of the integrin receptor. [54] Modification of the hydroxyl group of tetrac 
with alkyl chains carrying at least one amino group, will shift the antagonist strength of tetrac 
upward because of their ability to interact with the Arg recognition site in the propeller domain of 
integrin αvβ3. In addition to the number of nitrogen atoms, we strongly believe that the distance 
between the carboxylic acid and the amine groups will impact the activity of molecule [54,58]. In 
this study, we synthesized mono-amino tetrac (MAT) from tetrac in different approaches and 
analyzed its biological activity compared to DAT as well as its binding affinity with αvβ3 and 
molecular modeling [54]. 
In order to synthesize MAT, we initially began by treating tetrac 7 directly with 3-
15 
bromopropylamine 8 in different conditions but it did not work. Therefore, we decided to protect 
the amine group of 3-bromopropylamine 4 with tert-butyl carbamate (Boc) using di-tert-butyl 
dicarbonate (Boc2O) in the presence of triethylamine (TEA, 4 eq) in dichloromethane for 12 hours 
giving the desired 3-bromopropyl-tert-butylcarbamate 13 in 96% yield. [60] In order to have better 
reaction yields, we also protected the phenylacetic acid end of tetrac 7 using a protecting method 
that we previously published, by dissolving tetrac 7 and thionyl chloride in methanol under reflux 
conditions and compound 9 (methyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-
diiodophenyl)acetate) was obtained in 78 % yield. [59] Results from FTIR confirmed the 
production of protected tetrac 9 by the shift of the carbonyl (C=O) of the acid group of tetrac from 
1693 cm-1 to 1719 cm-1 as evidence of the carbonyl (C=O) of the ester group after protection. This 
was also confirmed by 1H NMR and 13CNMR data. [59] The -OH of 9 was then reacted with 3-
bromopropyl-tert-butylcarbamate 13 in the presence of potassium carbonate and acetone under 
reflux conditions to give protected compound 10 with a yield of approximately 93%. Using the 
potassium carbonate as mild base is very important for deprotonation of the phenol and for the 
reaction with alkyl bromide.  
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Scheme 2. (a) boron trifluoride diethyl etherate (BF3.Et2O), methanol, 24 h, dry conditions, room 
temperature, 62%; (b) alkyl bromide, acetone, potassium carbonate, reflux, 18 h, 65-80%;  (c) THF, 
MeOH, KOH 2M, 70-90%; (d) 3-bromopropyl-tert-butylcarbamate, potassium carbonate and acetone, 
reflux, 93%; (e) concentrated acetic acid, 78% (f) NH2NH2, ethanol. 
 
Subsequently, compound 10 was finally deprotected in the presence of concentrated acetic acid. 
A novel and efficient method to convert fully protected amino acids to its corresponding 
zwitterionic forms was developed. Design and synthesis of non-natural amino acids requires 
multiple protecting groups, and final manipulations of synthetic amino acids into their zwitterionic 
form typically involves isoelectric precipitation or laborious ion exchange chromatography. [61] 
Based on previously reported work by Hao et al., in order to avoid ion exchange chromatography 
and obtain zwitterionic amino acids after solvent removal, we employed acetic acid to 
simultaneously remove both the methyl ester and the Boc protecting groups. [62] Although Hao 
et al., completed the reaction in microwave conditions at 150 °C, we set the reaction in reflux in 
17 
highly concentrated acetic acid. This fully protected tetrac analog 10 was cleanly converted to 
zwitterion MAT in 78% yield after simple evaporation of solvents (AcOH and water) without any 
further purification or manipulation. 
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Scheme 3. Synthesis of DAT (a) potassium carbonate, 1-bromo-3-chloropropane, acetone, reflux; (b) 
concentrated HCl; ( c) acetone, sodium iodide, reflux, 26h; (d) 1, 3-diaminopropane, stirred for 2h, 1N 
sodium hydroxide 
 
DAT was also synthesized based on our previously reported patent as the reaction shown 
in scheme 3 by adding potassium carbonate to a solution of tetrac 7 and 1-bromo-3-chloropropane 
in acetone that was vigorously mixed to produce a white, thick suspension that was slowly (30 
min) heated to a gentle reflux (58-59 °C). [63] After 5.5 hours the reaction mixture was cooled to 
~ 45 °C, filtered and washed with dichloromethane. The filtrate was evaporated to oil, to which n-
Heptane is added. The white solids of dichloro-tetrac were allowed to stand overnight at room 
temperature and then filtered. The solids were washed with n-Heptane and dried under vacuum 
(room temperature). Dichloro-tetrac was brought up in ethanol and added to a solution of 
potassium hydroxide in ethanol. The resulting mixture was acidified with conc. hydrochloric acid 
in ethanol to an approximate pH of 1. The resulting suspension was evaporated to reduce the 
volume by half and deionized water was added. The mixture was cooled to room temperature and 
then filtered. The precipitate was washed with deionized water and dried at 45 °C under vacuum 
to yield chloro-tetrac 17. The chloro-tetrac was dissolved in acetone and added to a solution of 
18 
sodium iodide in acetone. The reaction mixture was heated to a gentle reflux (59-60 °C) for 26 h. 
The reaction mixture was evaporated to remove most of the acetone and the resulting solid was 
stirred with deionized water for 1 hour. The solids were filtered and washed with deionized water. 
The solid was dried at 45-50 °C under house vacuum for four days to give iodo-tetrac 18 as a pale 
yellow solid. Iodo-tetrac was slowly added to 1,3-diaminopropane while maintaining the 
temperature below 28 °C. The clear reaction mixture was stirred at room temperature for 2 hours. 
A solution of 1N sodium hydroxide was added and most of the solvent was evaporated at 50-55 
°C using a high vacuum pump. The crude diamino-tetrac was purified over silica gel (70-230 
mesh) eluting with a mixture of DCM: MeOH: 7N NH3 60:40:6. Pure fractions were collected and 
evaporated. The resulting mixture was stirred with a 2:3 mixture of ethanol: CH2C12. The solids 
were filtered and washed with a 1:1 mixture of ethanol:CH2D12. The product was dried at 45 °C 
overnight to give DAT. 
In vitro adhesion studies 
Adhesion of mammalian cells to the extracellular matrix (ECM) is mediated by protein-
protein and protein-carbohydrate interactions. Alterations in the expression of cell surface 
molecules lead to the dissemination of metastatic cells from tumor tissue. Cell surface molecules 
in glioma, which are important for their metastatic property, have been intensively investigated. 
Among these, integrins, which are heterodimeric integral membrane proteins, are involved in 
protein-protein mediated adhesion of cells to the extracellular matrix (ECM). 
Adhesion assay 
The 96-well plates polyvinyl chloride (PVC) were coated with 0.5 μg human fibrinogen 
dissolved in 50 μl H2O and incubated overnight at 4 
0C. Nonspecific binding sites were blocked 
with 200 μl of 2 % bovine serum albumin (BSA) solution in phosphate buffer saline (PBS). To 
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control for nonspecific adherence to the PVC surface, cell adhesion was also measured on non-
coated PVC plates. Glioma (U87) cells were detached with 0.05 % Trypsin EDTA and washed 
three times in assay-medium (serum-free RPMI medium). Test compounds (MAT, DAT and 
tetrac) were dissolved in assay medium and cells were incubated therein for 1 h. For the adhesion 
assays on PVC, the assay medium contained no BSA. To each coated well 1 X 105 cells were 
added, and after 1h nonadherent cells were removed by three consecutive washing steps with PBS. 
Cells were fixed with 4 % paraformaldehyde and stained in 0.5 % crystal violet in 20 % 
MeOH/PBS. Cells were washed extensively with H2O, solubilized with 1 % SDS, and the 
absorbance read was at 590 nm. 
Inhibition of glioblastoma cell adhesion by compounds  
Our cell adhesion studies showed the compounds have similar inhibition of glioma cell 
attachment to fibrinogen which was used as a control multifunctional adhesive protein that plays 
a major role in cellular events such as thrombosis, wound healing, and cancer. Studies have 
demonstrated that the β3 integrins, αvβ3 and αIIbβ3, serve as receptors for fibrinogen on various nucleated 
cells and platelets, respectively. Therefore, it will be interesting to understand the molecular basis of 
cell adhesion of synthesized in comparison to fibrinogen. To find the possible binding sites for 
tetrac, MAT and DAT, we used docking studies to screen the protein surface of the extracellular 
domain of αvβ3, the crystal structure. Inhibition of adhesion of the U87 cells to fibrinogen were 
tested with increasing concentration of tetrac, MAT and DAT. The cells were exposed to the 
compounds in medium for 1h, then aliquots of the medium with 1X 105 cells were seeded into a 
well precoated with fibrinogen and incubated for another hour. Non-adherent cells were washed 
off and adherent cells were quantified at 590 nm. Means of three values ± SD relative to cells 
adhering in the absence of compounds are shown. The cell adhesion to fibrinogen decreased 
20 
significantly (***P < 0.01) in a dose-dependent manner in the presence of compounds until cell 
binding completely blocked at 1 µM concentration. The inhibition of U87 cells to fibrinogen 
follows in the order of MAT >DAT > Tetrac at 0.01, 0.03, 0.1, 0.3 and 1 µM concentration. No 
significance was observed for the binding of tetrac to fibrinogen when compared to cells without 
any compounds. (Figure 5) 
 
Fig 5: Inhibition of U87 adhesion to fibrinogen. Means of three values ± SD relative to cells adhering in 
the absence of compounds are shown. ***P <0.001, **P <0.01, *P <0.05. 
 
In silico  
Drugs were screened against integrin αvβ3 by using Auto Dock Vina, software available 
from http://viba.scripps.edu/. The crystal structure of integrin αvβ3 (PDB id: 1L5G) was retrieved 
from the Protein Data Bank and the ligand 3D structure were saved in pdbqt format. The grid size 
along the x, y, z axis was set to 50, 50, 50 Å and the grid center along the x, y, z axis was set as 
28.98, 25.32, 19.34 Å, respectively to cover the protein. The interactions of integrin αvβ3 with the 
21 
drugs, hydrogen bonds and bond lengths were analyzed using pyMOL software. 
In silico studies  
Auto Dock Vina version 4.0 was employed for the docking of drugs to integrin αvβ3 protein 
and the binding affinities of docked compound were obtained. The binding affinity, number of 
hydrogen bonds formed and catalytic site residues involved in the complex is shown in Table 2 
and Figure 6 (a-c).  
22 
 
Figure 6. Tetrac , MAT, DAT docked in the crystal structure of the extracellular domain of αvβ3 integrin 
 
The tetrac (Figure 6A) exhibited binding score of -4.8 Kcal mol-1 and resulted in formation 
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of three hydrogen bonds with amino acids Arg 214 (2.6 Å),  Arg 216 (2.2 Å), Arg 216 (2.2 Å) of 
chain B. Whereas, the MAT (Figure 6B) exhibited binding score of -5.4 Kcal mol-1 and resulted 
in formation of six hydrogen bonds with amino acids residues Ile 147 (2.6 Å) of chain A and  Arg 
214 (2.6 Å), Asn 215 (3.3 Å),  Arg 215 (3.2 Å), Arg 216 (3.1 Å) of chain B and  Asp 5003 (2.1 Å) 
of chain C. The diamino-tetrac (Figure 6C) exhibited binding score of -5.1 Kcal mol-1 and resulted 
in formation of seven hydrogen bonds with amino acids Asp 146 (2.6 Å), ile 147 (2.5 Å), Asp 150 
(3.6 Å) of chain A and Asn 215 (3.2 Å), Arg 215 (3.4 Å), Arg 216 (3.2 Å) of chain B and Asp 
5003 (2.0 Å) of chain C. The docking results suggest that the MAT has a higher affinity to bind to 
the protein compared to diamino tetrac and tetrac. 
 
Table 2. Virtual screening of drugs docked to Integrin αvβ3 (IL5G) 
 
 
 
In vivo Mouse matrigel model of angiogenesis 
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Matrigel plug assays in mice were performed in accordance with institutional guidelines 
for animal safety and welfare. Female C57/B6 mice aged 5-6 weeks and body weights of 20 g 
were purchased from Taconic Farms (Hudson, NY, USA). Animals were maintained under 
specific pathogen-free conditions and housed four animals per cage, under controlled conditions 
of temperature (20-24° C) and humidity (60-70%) and a 12 h light/dark cycle. Water and food 
were provided ad libitum. The in vivo study was carried out in the animal facility of the Veterans 
Affairs (VA) Medical Center, Albany, NY, and the experimental protocol was approved by the 
VAIACUC. Mice were allowed to acclimatize for 5 d prior to the start of experiments. Matrigel 
Matrix High Concentration with growth factors was injected in four subcutaneous ways for each 
animal at 200 µl/animal. Animals in the control group were injected just with matrigel in 200 µl 
volume.  Animals in the groups were injected with 20 µg compound in 200 µl matrigel. All groups 
had three mice per group, with a total of 12 matrigel subcutaneous injection per group. At day 14 
post plug implant all animals were sacrificed and hemoglobin contents were quantitated using 
spectrophotometry. 
Determination of Hb levels 
Matrigel plug Hb content was indexed as a measure of new vascularity. Briefly, Matrigel plugs 
were placed into a 0.5 ml tube containing double distilled water and then homogenized for 5-10 
min. The samples were subjected to centrifugation at 4,000 rpm for 10 min and then the 
supernatants were collected. A volume of 50 μl of supernatant were mixed with 50 μl of Drabkin’s 
reagent and allowed to sit at room temperature for 15-30 min, after which 100 μl was placed in a 
96-well plate and absorbance measured at 540 nm with a Microplate Manager ELISA reader. Hb 
concentration was expressed as mg/ml based on comparison with a standard curve. Figure 7 
showed that tetrac had a higher activity when compared to MAT and DAT but when compared to 
25 
DAT, MAT had a higher activity.  
Figure 7. In vivo mouse matrigel model of angiogenesis  
Conclusion 
Angiogenesis is the formation of new blood vessels from preexisting blood vessels. Design 
and development of novel angiogenesis inhibitors based on targeting an integrin, has been 
validated as a target in several tumor types. Integrins are important ligands that play a critical role 
in the angiogenesis process, particularly blood formation and local release of vascular growth 
factors, and they are members of a family of cell surface receptors. Tetrac, a deaminated derivative 
of thyroid hormone, has an interaction site that is located at or near the RGD recognition site 
identified on integrin αvβ3’s binding pocket. In order to develop new angiogenesis inhibitors, we 
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synthesized novel amine derivatives of tetrac (containing mono and di amino group) and tested 
them for their anti-angiogenesis activity such as binding adhesion study, modeling study as well 
as in vivo mouse matrigel study.  Our data showed similar inhibition of glioma cell attachment to 
fibrinogen. To find the possible binding sites for tetrac, MAT, DAT, we used docking studies to 
screen the protein surface of the extracellular domain of αvβ3, the crystal structure. Inhibition of 
adhesion of the U87 cells to fibrinogen were tested with increasing concentration of tetrac, MAT 
and DAT. The cell adhesion to fibrinogen decreased significantly (***P < 0.01) in a dose-
dependent manner in the presence of compounds until cell binding completely blocked at 1 µM 
concentration. The inhibition of U87 cells to fibrinogen follows in the order of MAT >DAT > 
Tetrac at 0.01, 0.03, 0.1, 0.3 and 1 µM concentration. No significance was observed for the binding 
of tetrac to fibrinogen when compared to cells without any compounds. Auto Dock Vina version 
4.0 was employed for the docking of drugs to integrin αvβ3 protein and the binding affinities of 
docked compound were obtained. Mouse matrigel study also showed that tetrac still had higher 
activity compare to MAT and DAT but MAT showed better activity compare to DAT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
References 
 
1. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New england journal 
of medicine, 285(21), 1182-1186. 
2. Velazquez, O. C. (2007). Angiogenesis and vasculogenesis: Inducing the growth of new 
blood vessels and wound healing by stimulation of bone marrow–derived progenitor cell 
mobilization and homing. Journal of vascular surgery, 45(6), A39-A47. 
3. Rosca, E. V., Koskimaki, J. E., Rivera, C. G., Pandey, N. B., Tamiz, A. P., & Popel, A. S. 
(2011). Anti-angiogenic peptides for cancer therapeutics. Current Pharmaceutical 
Biotechnology, 12(8), 1101–1116. 
4. Risau, W., Sariola, H.., Zerwes, H. G., Sasse, J., Ekblom, P., Kemler, R., & Doetschman, 
T. (1988). Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid 
bodies. Development, 102(3), 471-478. 
5. Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nature medicine, 
6(4), 389. 
6. Vailhé, B., Vittet, D., & Feige, J. J. (2001). In vitro models of vasculogenesis and 
angiogenesis. Laboratory investigation, 81(4), 439. 
7. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646-674. 
8. Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nature 
reviews cancer, 3(6), 401-410. 
9. Wicki, A., & Christofori, G. (2008). The angiogenic switch in tumorigenesis. Tumor 
Angiogenesis, 67-88. 
10. Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell, 86(3), 353-364. 
11. Serini, G., Valdembri, D., & Bussolino, F. (2006). Integrins and angiogenesis: a sticky 
business. Experimental cell research, 312(5), 651-658. 
12. Hynes, R. O. (2002). A reevaluation of integrins as regulators of angiogenesis. Nature 
medicine, 8(9), 918. 
13. Zitzmann, S., Ehemann, V., & Schwab, M. (2002). Arginine-glycine-aspartic acid (RGD)-
peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer research, 62(18), 
28 
5139-5143. 
14. Bello, L., et al. (2001). αvβ3 and αvβ5 integrin expression in glioma periphery. 
Neurosurgery, 49(2), 380-390. 
15. Gruber, G. et al. (2005). Correlation between the tumoral expression of β3-integrin and 
outcome in cervical cancer patients who had undergone radiotherapy. British journal of 
cancer, 92(1), 41-46. 
16. Landen, C. N. et al. (2008). Tumor-selective response to antibody-mediated targeting of 
αvβ3 integrin in ovarian cancer. Neoplasia 10, 1259–126. 
17. Hosotani, R. et al. (2002). Expression of integrin αvβ3 in pancreatic carcinoma: relation to 
MMP-2 activation and lymph node metastasis. Pancreas 25, e30–35. 
18. McCabe, N. P., De, S., Vasanji, A., Brainard, J. & Byzova, T. V. (2007). Prostate cancer 
specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling. Oncogene 
26, 6238–6243. 
19. Takayama, S. et al. (2005). The relationship between bone metastasis from human breast 
cancer and integrin αvβ3 expression. Anticancer Res. 25, 79–83. 
20. Liapis, H., Flath, A. & Kitazawa, S. (1996). Integrin αVβ3 expression by bone-residing 
breast cancer metastases. Diagn. Mol. Pathol. 5, 127–135. 
21. Sloan, E. K. et al. (2006). Tumor-specific expression of αvβ3 integrin promotes 
spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20. 
22. Felding-Habermann, B. et al.  (2001). Integrin activation controls metastasis in human 
breast cancer. Proc. Natl Acad. Sci. USA 98, 1853–1858. 
23. Albelda, S. M. et al. (1990). Integrin distribution in malignant melanoma: association of 
the β3 subunit with tumor progression. Cancer Res. 50, 6757–6764. 
24. Danen, E. H. et al. (1994). Emergence of α5β1 fibronectin- and αvβ3 vitronectin-receptor 
expression in melanocytic tumour progression. Histopathology 24, 249–256. 
25. Bates, R. C. et al. (2005). Transcriptional activation of integrin β6 during the epithelial-
mesenchymal transition defines a novel prognostic indicator of aggressive colon 
carcinoma. J. Clin. Invest. 115, 339–347. 
26. Hazelbag, S. et al. (2007). Overexpression of the αvβ6 integrin in cervical squamous cell 
carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316–324. 
29 
27. Slack-Davis, J. K., Atkins, K. A., Harrer, C., Hershey, E. D. & Conaway, M. (2009). 
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. 
Cancer Res. 69, 1469–1476. 
28. Adachi, M. et al. (2000). Significance of integrin α5 gene expression as a prognostic factor 
in node-negative non-small cell lung cancer. Clin. Cancer Res. 6, 96–101. 
29. ? 
30. Diaz, L. K. et al. (2005). β4 integrin subunit gene expression correlates with tumor size 
and nuclear grade in early breast cancer. Mod. Pathol. 18, 1165–1175. 
31. Friedrichs, K. et al. (1995). High expression level of α6 integrin in human breast carcinoma 
is correlated with reduced survival. Cancer Res. 55, 901–906. 
32. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Nat. Rev. Cancer 2008, 8, 604–617. 
33. Serini, G.; Valdembri, D.; Bussolino, F. Exp. Cell Res. 2006, 312, 651–8. 
34. Hynes, R. O. Nat. Med. 2002, 8, 918–921. 
35. Pierschbacher, M. D.; Ruoslahti, E. Nature 1984, 309, 30–33. 
36. Jaracz, S.; Chen, J.; Kuznetsova, L. V; Ojima, I. Bioorg. Med. Chem. 2005, 13, 5043–
5054. 
37. Zitzmann, S.; Ehemann, V.; Schwab, M. Cancer Res. 2002, 62, 5139–43. 
38. Bogdanowich‐ Knipp, S. J., Chakrabarti, S., Siahaan, T. J., Williams, T. D., & Dillman, 
R. K. (1999). Solution stability of linear vs. cyclic RGD peptides. Chemical Biology & 
Drug Design, 53(5), 530-541. 
39. Li, Z. J., & Cho, C. H. (2012). Peptides as targeting probes against tumor vasculature for 
diagnosis and drug delivery. Journal of translational medicine, 10(1), S1. 
40. Luidens, M. K., Mousa, S. A., Davis, F. B., Lin, H. Y., & Davis, P. J. (2010). Thyroid 
hormone and angiogenesis. Vascular pharmacology, 52(3), 142-145. 
41. Bridoux, A., Cui, H., Dyskin, E., Yalcin, M., & Mousa, S. A. (2009). Semisynthesis and 
pharmacological activities of Tetrac analogs: angiogenesis modulators. Bioorganic & 
medicinal chemistry letters, 19(12), 3259-3263. 
42. Yalcin, et al. (2010). Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest 
growth of medullary carcinoma of the thyroid. The Journal of Clinical Endocrinology & 
Metabolism, 95(4), 1972-1980. 
30 
43. Mousa, et al. (2008). Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks 
angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth 
factor. Angiogenesis, 11(2), 183-190. 
44. Mousa, et al. (2012). Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid 
hormone stimulation of non-small cell lung cancer cells in vitro and its growth in 
xenografts. Lung Cancer, 76(1), 39-45. 
45. Yoshida, T., Gong, J., Xu, Z., Wei, Y., & Duh, E. J. (2012). Inhibition of pathological 
retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). 
Experimental eye research, 94(1), 41-48. 
46. Yalcin, et al. (2010). Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest 
growth of medullary carcinoma of the thyroid. The Journal of Clinical Endocrinology & 
Metabolism, 95(4), 1972-1980. 
47. Bharali, D. J., Yalcin, M., Davis, P. J., & Mousa, S. A. (2013). Tetraiodothyroacetic acid-
conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast 
cancer. Nanomedicine, 8(12), 1943-1954. 
48. Yalcin et al. (2009). Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit 
growth of human renal cell carcinoma xenografts. Anticancer research, 29(10), 3825-3831. 
49. Srinivasan, M., Rajabi, M., & Mousa, S. A. (2015). Multifunctional nanomaterials and their 
applications in drug delivery and cancer therapy. Nanomaterials, 5(4), 1690-1703. 
50. Srinivasan, M., Rajabi, M., & Mousa, S. A. (2016). Nanobiomaterials in Cancer Therapy. 
In Nanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials (Vol. 7, p. 57). 
Elsevier Amsterdam. 
51. Rajabi, M., Srinivasan, M., & Mousa, S. A. (2016). Nanobiomaterials in Drug Delivery. In 
Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials (Vol. 9, p. 1). 
Elsevier Amsterdam. 
52. Rajabi, M., Srinivasan, M., & Mousa, S. A. (2016). Nanobiomaterials in Drug Delivery. In 
Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials (Vol. 9, p. 1). 
Elsevier Amsterdam. 
53. Rajabi, M., Sudha, T., Darwish, N. H., Davis, P. J., & Mousa, S. A. (2016). Synthesis of 
MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-
31 
angiogenesis modulator. Bioorganic & Medicinal Chemistry Letters, 26(16), 4112-4116. 
54. Lin, H.-Y.; Chin, Y.-T.; Nana, A. W.; Shih, Y.-J.; Lai, H.-Y.; Tang, H.-Y.; Leinung, M.; 
Mousa, S. A.; Davis, P. J. (2016) Steroids, 15, 943–958. 
55. Wu, S. Y., Green, W. L., Huang, W. S., Hays, M. T., & Chopra, I. J. (2005). Alternate 
pathways of thyroid hormone metabolism. Thyroid, 15(8), 943-958. 
56. Still, W. C., Kahn, M., & Mitra, A. (1978). Rapid chromatographic technique for 
preparative separations with moderate resolution. The Journal of Organic Chemistry, 
43(14), 2923-2925. 
57. Bridoux, A.; Khan, R. A.; Chen, C.; Chevé, G.; Cui, H.; Dyskin, E.; Yasri, A.; Mousa, S. 
(2011) A. J. Enzyme Inhib. Med. Chem., 26, 871–88 
58. Huang, A. Y.-T.; Tsai, C.-H.; Chen, H.-Y.; Chen, H.-T.; Lu, C.-Y.; Lin, Y.-T.; Kao, C.-L. 
(2013). Chem. Commun. (Camb)., 49, 5784–6. 
59. Moloney, M. G. (2002). Excitatory amino acids. Natural product reports, 19(5), 597-616. 
60. Hao, J., Reinhard, M., Henry, S. S., Seest, E. P., Belvo, M. D., & Monn, J. A. (2012). 
Simple conversion of fully protected amino acids to zwitterions. Tetrahedron Letters, 
53(12), 1433-1434. 
61. Davis, P. J., Davis, F. B., Mousa, S. A., Glinksy, G. V., & Hercbergs, A. (2015). U.S. 
Patent No. 9,220,788. Washington, DC: U.S. Patent and Trademark Office. 
 
